Clinical Trial Update: Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation and expansion study is evaluating ZE46-0134 in adults with FLT3-mutated or spliceosome-mutated relapsed/refractory acute myeloid leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ZE46-0134

Snippet

Sponsor: Lomond Therapeutics Holdings, Inc. | Conditions: AML With Gene Mutations | Phase 1 | Status: RECRUITING